Sonoma Pharmaceuticals, Inc.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) and Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Profitability This table compares Orion OYJ and Sonoma

Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Indivior (NASDAQ: INDV - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Insider and Institutional Ownership 1.9% of Sonoma Pharmaceuticals shares

Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Institutional and Insider Ownership 86.2% of Harmony Biosciences

Total revenue increased 60% year over year to $6.4 million Net loss per share decreased 88% compared to the prior-year quarter Gross margin expanded to 40% as operating expenses remained stable FDA clearance and new global distributors support continued commercial growth BOULDER, CO / ACCESS Newswire / August 6, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal quarter ended June 30, 2026. "Our first quarter results demonstrate that Sonoma has reached an important inflection point," said Amy Trombly, CEO of Sonoma.